Latest Publications
Control of Nitrosamine Impurities in Human Drugs
In February 2021, the FDA issued a guidance aimed at preventing unacceptable levels of nitrosamine impurities in pharmaceutical products. This guidance required a risk assessment to be completed by March 31, 2021. This isRead more
Recent research on bedaquiline selected for the November cover of Acta Crystallographic
Improved Pharma is pleased to announce the open-source publication of research into finding new salts of bedaquiline, an important drug for the treatment of tuberculosis. The drug is currently marketed in the US asRead more
Improved Pharma presenting at AAPS 2020 PHARMSCI 360 with Rapid Fire Presentation and Poster
WEST LAFAYETTE, IND. (PRWEB) OCTOBER 26, 2020 Interact with us via poster number 924440 and the Advances and Innovation in Formulation Development Rapid Fire session. On Wednesday October 28th, Dr. Pamela Smith, COO of ImprovedRead more
Published book chapter on Solid-State Characterization
Improved Pharma COO Pamela Smith is co-author of a chapter in the latest edition of Specification of Drug Substances and Products: Development and Validation of Analytical Methods. The chapter, Solid-State Characterization – Method Development andRead more
Excipient Effects on Drug Product Performance
Traditionally, excipients utilized for the development of pharmaceutically-marketed drug products have been considered largely inert. Excipients are added to formulations for a variety of reasons that may include assisting processability of the drug product formulation,Read more
Improved Pharma Announces New UV-Vis Capabilities and Expanded Dissolution Services
WEST LAFAYETTE, IND. (PRWEB) SEPTEMBER 15, 2020 Improved Pharma has expanded their offerings by acquiring S. I. Photonics’ top-of-the-line spectrophotometer, model 440. This model has a high sensitivity, low noise CCD detector that enables the collectionRead more